Panbela Therapeutics (PBLA) Competitors $0.15 0.00 (0.00%) As of 09/5/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PBLA vs. SLRX, SRNE, LIPO, PTIX, GLMD, CANF, SPRC, ADXS, UPC, and ATXIShould you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include Salarius Pharmaceuticals (SLRX), Sorrento Therapeutics (SRNE), Lipella Pharmaceuticals (LIPO), Atrinsic (PTIX), Galmed Pharmaceuticals (GLMD), Can-Fite BioPharma (CANF), SciSparc (SPRC), Ayala Pharmaceuticals (ADXS), Universe Pharmaceuticals (UPC), and Avenue Therapeutics (ATXI). These companies are all part of the "pharmaceutical products" industry. Panbela Therapeutics vs. Its Competitors Salarius Pharmaceuticals Sorrento Therapeutics Lipella Pharmaceuticals Atrinsic Galmed Pharmaceuticals Can-Fite BioPharma SciSparc Ayala Pharmaceuticals Universe Pharmaceuticals Avenue Therapeutics Salarius Pharmaceuticals (NASDAQ:SLRX) and Panbela Therapeutics (NASDAQ:PBLA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings. Does the media refer more to SLRX or PBLA? In the previous week, Salarius Pharmaceuticals had 1 more articles in the media than Panbela Therapeutics. MarketBeat recorded 1 mentions for Salarius Pharmaceuticals and 0 mentions for Panbela Therapeutics. Salarius Pharmaceuticals' average media sentiment score of 1.00 beat Panbela Therapeutics' score of 0.00 indicating that Salarius Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Salarius Pharmaceuticals Positive Panbela Therapeutics Neutral Which has more risk & volatility, SLRX or PBLA? Salarius Pharmaceuticals has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, Panbela Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Is SLRX or PBLA more profitable? Panbela Therapeutics' return on equity of 0.00% beat Salarius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Salarius PharmaceuticalsN/A -556.47% -192.35% Panbela Therapeutics N/A N/A -302.61% Which has higher valuation & earnings, SLRX or PBLA? Salarius Pharmaceuticals is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSalarius PharmaceuticalsN/AN/A-$5.58M-$43.48-0.11Panbela TherapeuticsN/AN/A-$25.26M-$71.130.00 Do institutionals and insiders have more ownership in SLRX or PBLA? 11.9% of Salarius Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.4% of Panbela Therapeutics shares are owned by institutional investors. 1.2% of Salarius Pharmaceuticals shares are owned by insiders. Comparatively, 0.0% of Panbela Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummarySalarius Pharmaceuticals beats Panbela Therapeutics on 7 of the 10 factors compared between the two stocks. Get Panbela Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PBLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBLA vs. The Competition Export to ExcelMetricPanbela TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$728K$952.75M$5.83B$9.93BDividend YieldN/A4.84%6.70%4.52%P/E Ratio0.001.1276.1526.11Price / SalesN/A26.54562.61123.62Price / CashN/A19.5636.9959.28Price / Book-0.016.7311.486.09Net Income-$25.26M-$3.82M$3.29B$266.51M7 Day Performance-5.00%0.54%1.27%0.46%1 Month Performance-5.00%12.25%7.94%4.59%1 Year Performance-58.33%28.10%62.94%26.04% Panbela Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBLAPanbela Therapeutics0.0817 of 5 stars$0.15flatN/AN/A$728KN/A0.006Gap DownSLRXSalarius Pharmaceuticals0.945 of 5 stars$5.76+2.5%N/A-79.7%$2.87MN/A-0.1320Short Interest ↓SRNESorrento Therapeutics0.7919 of 5 stars$0.01+25.0%N/A-38.3%$2.76M$60.32M0.00800Gap DownLIPOLipella Pharmaceuticals0.8477 of 5 stars$0.590.0%N/A-81.5%$2.74M$536.36K-0.154Short Interest ↑PTIXAtrinsic0.2891 of 5 stars$3.97-12.0%N/A-68.3%$2.66MN/A-0.302Negative NewsUpcoming EarningsShort Interest ↑GLMDGalmed Pharmaceuticals0.6938 of 5 stars$1.39-1.4%N/A-60.3%$2.33MN/A-0.0820Short Interest ↑CANFCan-Fite BioPharma2.9474 of 5 stars$0.66+0.8%$14.00+2,036.8%-72.0%$2.32M$674K-0.378Analyst ForecastShort Interest ↓SPRCSciSparc0.5472 of 5 stars$4.23+0.2%N/A-67.3%$2.26M$1.31M0.004Gap UpHigh Trading VolumeADXSAyala PharmaceuticalsN/A$0.03-34.7%N/A+66.5%$2.17M$3.24M0.0020Gap DownUPCUniverse PharmaceuticalsN/A$3.77+5.9%N/A-99.8%$2.12M$19.29M0.00220Gap DownATXIAvenue Therapeutics1.8196 of 5 stars$0.58-0.3%N/A-73.8%$1.84MN/A0.034Positive NewsGap Down Related Companies and Tools Related Companies Salarius Pharmaceuticals Competitors Sorrento Therapeutics Competitors Lipella Pharmaceuticals Competitors Atrinsic Competitors Galmed Pharmaceuticals Competitors Can-Fite BioPharma Competitors SciSparc Competitors Ayala Pharmaceuticals Competitors Universe Pharmaceuticals Competitors Avenue Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBLA) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersScientists Discover Untapped Energy Source in Heart of USACrash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredHamilton’s 100-to-1 tradePorter Stansberry has made a career out of bold calls that go against the mainstream narrative — from the 1998...Porter & Company | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Goldco Precious Metals | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Panbela Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Panbela Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
